共 50 条
Dexmedetomidine against intestinal ischemia/reperfusion injury: A systematic review and meta-analysis of preclinical studies
被引:4
|作者:
Hou, Min
[1
]
Chen, Feng
[1
]
He, Yao
[1
]
Tan, Zhiguo
[1
]
Han, Xuena
[1
]
Shi, Yajing
[1
]
Xu, Yunpeng
[1
]
Leng, Yufang
[1
,2
,3
]
机构:
[1] Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Peoples R China
[2] Lanzhou Univ, Dept Anesthesiol, Hosp 1, Lanzhou 730000, Peoples R China
[3] Lanzhou Univ, Clin Med Coll 1, 199 Donggang Rd West, Lanzhou 730000, Peoples R China
关键词:
Intestinal ischemia/reperfusion injury;
Dexmedetomidine;
Preclinical studies;
Meta-analysis;
Systematic review;
ISCHEMIA-REPERFUSION INJURY;
TOLL-LIKE RECEPTORS;
CELL-DEATH;
ISCHAEMIA/REPERFUSION INJURY;
APOPTOSIS;
INFLAMMATION;
FERROPTOSIS;
CONTRIBUTE;
FAILURE;
D O I:
10.1016/j.ejphar.2023.176090
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Background: Intestinal ischemia/reperfusion injury (IRI) is a multifactorial, complex pathophysiological process in clinical settings. In recent years, intestinal IRI has received increasing attention due to increased morbidity and mortality. To date, there are no effective treatments. Dexmedetomidine (DEX), a highly selective alpha 2-adrenergic receptor agonist, has been demonstrated to be effective against intestinal IRI. In this systematic review and metaanalysis, we evaluated the efficacy and potential mechanisms of DEX as a treatment for intestinal IRI in animal models. Methods: Five databases (PubMed, Embase, Web of Science, Cochrane Library, and Scopus) were searched until March 15, 2023. Using the SYRCLE risk bias tool, we assessed methodological quality. Statistical analysis was conducted using STATA 12 and R 4.2.2. We analyzed the related outcomes (mucosa damage-related indicators; inflammation-relevant markers, oxidative stress markers) relied on the fixed or random-effects models. Results: There were 15 articles including 18 studies included, and 309 animals were involved in the studies. Compared to the model groups, DEX improved intestinal IRI. DEX decreased Chiu's score and serum diamine oxidase (DAO) level. DEX reduced the level of inflammation-relevant markers (interleukin (IL)-1 beta, IL-6, tumor necrosis factor (TNF)-alpha). DEX also improved oxidative stress (decreased malondialdehyde (MDA), increased superoxide dismutase (SOD)). Conclusions: DEX's effectiveness in ameliorating intestinal IRI has been demonstrated in animal models. Antioxidation, anti-inflammation, anti-apoptotic, anti-pyroptosis, anti-ferroptosis, enhancing mitophagy, reshaping the gut microbiota, and gut barrier protection are possible mechanisms. However, in light of the heterogeneity and methodological quality of these studies, further well-designed preclinical studies are warranted before clinical implication.
引用
收藏
页数:15
相关论文